NYSDOH has approved Wren Laboratories’ NETest® 2.0!
A major advance in precision care for neuroendocrine tumors — accurate diagnosis, real-time monitoring, and treatment-response prediction.
More: https://t.co/brB3TCIl5f
Wren Laboratories Announces Acquisition of Pure Diagnostic, Unifying Clinical Laboratory Operations Under the Wren Brand
Read more: Wren Laboratories Announces Acquisition of Pure Diagnostic, Unifying Clinical Laboratory Operations Under the Wren Brand | Newswise
Proud moment! Wren Laboratories achieved ISO 15189 accreditation in record time after auditors called our systems “super-human” and converted the gap audit straight to accreditation.
Quality. Precision. Excellence. #ISO15189#Healthcare#Lab
Thanks for joining our quizz on liquid biopsies for NETs last week! The odd one out is Caspases. They’re key in apoptosis, not used as biomarkers for NETs. CTCs, cfDNA, and Exosomes are crucial for detecting NETs. Stay tuned for more! #WrenLabs#LiquidBiopsy#NETs
Liquid biopsies can detect neuroendocrine tumors (NETs) through various biomarkers, but can you spot the odd one out? Find out why next Monday! #WrenLabs#LiquidBiopsy#NETS
Advancing cancer diagnostics with liquid biopsy! Non-invasive tech detects & monitors cancer through blood tests. Key points:
Non-invasive, Early detection, Comprehensive insights, Clinical use in cancers, FDA-approved
#LiquidBiopsy#CancerDiagnostics#MedicalInnovation
🌟 Wren Laboratories announces Dr. Abdel Halim as our new CEO & CSO, leading our mission to enhance precision medicine and expand into biopharma services. #Innovation#Biotech#Leadership
🚀 Big news from Wren Laboratories! We’re excited to unveil our dynamic executive leadership team and our 2024 commercial strategy overhaul. Get ready for innovation and growth in diagnostic solutions. #Healthcare#Diagnostics#Leadership
It's NET Cancer Day! Our latest blog post details some of the symptoms for various forms of Neuroendocrine Cancer - please share. You could save a life. https://t.co/dmDYeyBAPL
A 2020 survey by the International Neuroendocrine Cancer Alliance revealed that the average time to a diagnosis for a North American NET patient is 6.44 years. When finally diagnosed, >50% presented with neuroendocrine cancer that had metastasized. https://t.co/JlBYgpnEs1